Exagen Management

Management criteria checks 1/4

Exagen’s CEO is John Aballi, appointed in Oct 2022, he has a tenure of less than a year. His total yearly compensation is US$1.4m, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. He directly owns 0.5% of the company’s shares, worth US$240.4k. The average tenure of the management team and the board of directors is less than a year and 3.4yrs respectively.

Key information

John Aballi

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage7.9%
CEO tenureless than a year
CEO ownership0.5%
Management average tenureless than a year
Board average tenure3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Aballi's remuneration changed compared to Exagen's earnings?
DateTotal Comp.SalaryCompany Earnings
Dec 31 2022US$1mUS$111k

-US$47m

Compensation vs Market: John's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD402.55K).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


CEO

John Aballi (37 yo)

less than a year

Tenure

US$1,409,342

Compensation

Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022. Most recently he served as SVP, General Manager, Urology & CLIA COO at Veracyte Inc. Mr. Aba...


Leadership Team

NamePositionTenureCompensationOwnership
Tina Nova
Executive Chairman of Board3.8yrsUS$89.68k0%
$ 0
John Aballi
CEO, President & Directorless than a yearUS$1.41m0.53%
$ 240.4k
Kamal Adawi
CFO & Corporate Secretary5.9yrsUS$1.04m0.28%
$ 125.3k
Mark Hazeltine
Chief Business Officer1.3yrsUS$1.04m1.13%
$ 508.0k
Ryan Douglas
Investors Relations Officerno datano datano data
John Wegener
Senior Vice President of Sales and Marketing9.5yrsno datano data
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Boardless than a yearno datano data
Michael Nerenberg
Chief Medical Officerno datano datano data

0.6yrs

Average Tenure

50.5yo

Average Age

Experienced Management: E08A's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Tina Nova
Executive Chairman of Board3.8yrsUS$89.68k0%
$ 0
John Aballi
CEO, President & Directorless than a yearUS$1.41m0.53%
$ 240.4k
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board3.4yrsno datano data
Kenneth Bloom
Member of Breast Cancer Advisory Boardno datano datano data
Mark Pegram
Member of Breast Cancer Advisory Boardno datano datano data
Bruce Robertson
Independent Director3.8yrsUS$33.75k0%
$ 0
Thomas Williams
Member of Breast Cancer Advisory Boardno datano datano data
Brian Birk
Independent Director14.8yrsUS$103.68k0%
$ 0
Michael Press
Member of Breast Cancer Advisory Boardno datano datano data
Lyndsay Harris
Member of Breast Cancer Advisory Boardno datano datano data
Arthur Weinstein
Chairman of Scientific Advisory Board3.4yrsUS$130.00kno data
Frank Stokes
Additional Independent Director1.9yrsUS$86.68k0%
$ 0

3.4yrs

Average Tenure

63yo

Average Age

Experienced Board: E08A's board of directors are considered experienced (3.4 years average tenure).